Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more
Tenaya Therapeutics Inc (TNYA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.188x
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has a cash flow conversion efficiency ratio of -0.188x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.60 Million) by net assets ($82.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tenaya Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tenaya Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenaya Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiiangsu Times Textile Technology Co.LTD
SHE:001234
|
-0.047x |
|
India Motor Parts and Accessories Limited
NSE:IMPAL
|
0.005x |
|
Nova Klúbburinn hf.
IC:NOVA
|
N/A |
|
Niko Semiconductor Co Ltd
TWO:3317
|
0.018x |
|
Quipt Home Medical Corp
NASDAQ:QIPT
|
0.260x |
|
Laser Tek Taiwan Co Ltd
TWO:6207
|
0.037x |
|
Aurskog Sparebank
OL:AURG
|
-0.204x |
|
Shaanxi Meineng Clean Energy Corp. Ltd. A
SHE:001299
|
N/A |
Annual Cash Flow Conversion Efficiency for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tenaya Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.85 Million | $-90.50 Million | -0.975x | -33.13% |
| 2023-12-31 | $139.42 Million | $-102.07 Million | -0.732x | -70.63% |
| 2022-12-31 | $243.38 Million | $-104.42 Million | -0.429x | -96.52% |
| 2021-12-31 | $278.53 Million | $-60.81 Million | -0.218x | +14.11% |
| 2020-12-31 | $139.44 Million | $-35.45 Million | -0.254x | -146.14% |
| 2019-12-31 | $-43.74 Million | $-24.10 Million | 0.551x | -- |